This content is machine translated Urothelial carcinoma Immune and targeted therapy options: Evidence situation 2025/2026 The treatment of urothelial carcinoma has developed significantly in recent years. Modern immunotherapies, antibody-drug conjugates (ADCs) and targeted substances complement conventional chemotherapies and increasingly enable individualized treatment strategies. New data...…
View Post 12 min This content is machine translated NSCLC Bispecific antibodies for rare EGFR mutations Rare EGFR mutations such as exon 20 insertion changes have long been considered a therapeutic dead end in non-small cell lung cancer (NSCLC). Current data show that innovative mechanisms of...…
